Ads
related to: hcv polymerase inhibitors for diabetes management research center- Download A Co-Pay Coupon
Eligible Patients May Pay As Little
As $5 Per Co-Pay For A Treatment
- Hep C Treatment Info
Ready To Treat Your Hep C?
Learn About A Treatment Option Here
- Talk To Your Provider
Download A Conversation Guide And
Learn About A Treatment Option Here
- Risks Of Hepatitis C
Read About The Risks Of Hep C And
Explore A Hep C Treatment Here.
- Find A Hep C Provider
Ready To Take The Next Step? Find
A Hep C Provider Near You Today!
- Patient Support Program
Looking For Financial Assistance &
Insurance Support? Learn More Here.
- Download A Co-Pay Coupon
Search results
Results From The WOW.Com Content Network
The discovery of NS5A inhibitors took place within the context of a pursuit for a treatment for HCV. NS5A is among the seven nonstructural proteins that form a complex with viral RNA within infected cells to initiate HCV replication. [45] HCV research has produced several DAAs including NS3A, NS4A and NS5B inhibitors, as well as NS5A inhibitors ...
Moreover, NS5A is a key mediator in regulating host cell function and activity upon HCV infection. [4] Therefore, NS5A has been extensively studied in HCV research also due to its capability to regulate the interferon (IFN) response of the host cells. Because NS5A exerts functionally essential effects in regulation of viral replication ...
It acts as a NS5b polymerase inhibitor. [1] [2] [3] References This page was last edited on 23 March 2024, at 09:51 (UTC). Text is available under ...
HCV genome. Nonstructural protein 5B (NS5B) is a viral protein found in the hepatitis C virus (HCV). [1] It is an RNA-dependent RNA polymerase, having the key function of replicating HCV's viral RNA by using the viral positive RNA strand as a template to catalyze the polymerization of ribonucleoside triphosphates (rNTP) during RNA replication.
The virus is internalized and the nucleocapsid is released into the cytoplasm of the hepatocyte after binding with the receptor. The NS5B protein, which is an RNA-dependent RNA polymerase, catalyzes hepatitis C virus replication. [10] The hepatitis C virus can cause acute infection but most patients are asymptomatic upon exposure.
Current research is focused on small-molecule inhibitors of the viral protease, RNA polymerase and other nonstructural genes. Two agents— boceprevir by Merck [ 66 ] and telaprevir by Vertex Pharmaceuticals —both inhibitors of NS3 protease were approved for use on May 13, 2011, and May 23, 2011, respectively.
It is a member of a class of antiviral drugs known as protease inhibitors. [3] Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3/4A serine protease. [4] Telaprevir is only indicated for use against hepatitis C genotype 1 viral infections and has not been proven to be safe or effective when used for other genotypes of the virus.
Glecaprevir (INN, [1]) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals. [2] It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir.
Ad
related to: hcv polymerase inhibitors for diabetes management research center